nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.08.2017 | Systematic Review

Treatment of Porokeratosis: A Systematic Review

verfasst von: Till Weidner, Tanja Illing, Diana Miguel, Peter Elsner

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Porokeratosis (PK) is a rare skin disease of unknown etiology. It consists of a keratinization disorder, which may appear in several clinical forms and can undergo malignant transformation. The histopathological hallmark of PK is the cornoid lamella. While many topical, systemic, and surgical treatment modalities for PK have been described, no randomized controlled trials have been performed yet. Because of a lack of treatment standards for PK, European and international guidelines cannot be created.

Objective

The aim of this systematic review is to outline options for treating PK.

Methods

We performed a systematic literature search in an electronic database for published literature. A total of 88 articles fulfilling our inclusion criteria were found.

Results

There were no randomized controlled trials on the treatment of PK, but mainly case reports and case series. Porokeratosis of Mibelli showed the best outcomes after treatment with imiquimod cream and linear PK responded well to topical or systemic retinoids. Topical vitamin D acid derivatives may be the best therapeutic option for disseminated PK. Surgical interventions and cryotherapy may be preferred in areas where the use of topical agents is difficult or contraindicated.

Conclusion

To offer patients with PK an evidence-based high-quality standardized therapy, randomized controlled trials are needed.

Allegra F. The man behind the eponym. Vittorio Mibelli and the tale of “porokeratosis”. Am J Dermatopathol. 1986;8(2):169–72.PubMedCrossRef

Levitt JO, Keeley BR, Phelps RG. Treatment of porokeratosis of Mibelli with cantharidin. J Am Acad Dermatol. 2013;69(5):e254–5. doi:10.1016/j.jaad.2013.06.021.PubMedCrossRef

Kanitakis J. Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features. Eur J Dermatol. 2014;24(5):533–44. doi:10.1684/ejd.2014.2402.PubMed

Sertznig P, von Felbert V, Megahed M. Porokeratosis: present concepts. J Eur Acad Dermatol Venereol. 2012;26(4):404–12. doi:10.1111/j.1468-3083.2011.04275.x.PubMedCrossRef

Wade TR, Ackerman AB. Cornoid lamellation: a histologic reaction pattern. Am J Dermatopathol. 1980;2(1):5–15.PubMedCrossRef

Sasson M, Krain AD. Porokeratosis and cutaneous malignancy: a review. Dermatol Surg. 1996;22(4):339–42.PubMedCrossRef

Lederman JS, Sober AJ, Lederman GS. Immunosuppression: a cause of porokeratosis? J Am Acad Dermatol. 1985;13(1):75–9.PubMedCrossRef

Vire G, Latour D, King LE Jr. Porokeratosis and immunosuppression. J Am Acad Dermatol. 1986;14(4):683–4.PubMedCrossRef

Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol. 1998;8(7):459–65.PubMed

10.

Zhang SQ, Jiang T, Li M, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet. 2012;44(10):1156–60. doi:10.1038/ng.2409.PubMedCrossRef

11.

Zhou Y, Liu J, Fu X, et al. Identification of three novel frameshift mutations of the MVK gene in four Chinese families with disseminated superficial actinic porokeratosis. Br J Dermatol. 2013;169(1):193–5. doi:10.1111/bjd.12224.PubMedCrossRef

12.

Neumann RA, Knobler RM, Jurecka W, Gebhart W. Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions. J Am Acad Dermatol. 1989;21(6):1182–8.PubMedCrossRef

13.

Kawara S, Oiso N, Kawada A. Disseminated superficial actinic porokeratosis in a patient undergoing treatment with long-term narrowband ultraviolet B for psoriasis. J Dermatol. 2011;38(6):585–7. doi:10.1111/j.1346-8138.2010.01099.x.PubMedCrossRef

14.

Parish JL. Topical vitamin D3 analogues: unapproved uses, dosages, or indications. Clin Dermatol. 2002;20(5):558–62.PubMedCrossRef

15.

Nakamura Y, Yamaguchi M, Nakamura A, Muto M. Calcipotriol and adapalene therapy for disseminated superficial actinic porokeratosis. Indian J Dermatol Venereol Leprol. 2014;80(4):373–4. doi:10.4103/0378-6323.136981.PubMedCrossRef

16.

Noborio R, Morita A. Split-face trial of CO(2) laser-induced ring abrasion and high-dose tacalcitol in the treatment of disseminated superficial actinic porokeratosis. J Dermatol. 2012;39(10):879–80. doi:10.1111/j.1346-8138.2011.01461.x.PubMedCrossRef

17.

Abe M, Yokoyama Y, Ishikawa O. Successful treatment of disseminated superficial actinic porokeratosis with tacalcitol lotion. J Dermatol. 2010;37(10):913–5. doi:10.1111/j.1346-8138.2010.00902.x.PubMedCrossRef

18.

Asawanonda P, Noppakun N, Huiprasert P. Seborrheic keratosis-like porokeratosis: a case report. Dermatol Online J. 2005;11(1):18.PubMed

19.

Bohm M, Luger TA, Bonsmann G. Disseminated superficial actinic porokeratosis: treatment with topical tacalcitol. J Am Acad Dermatol. 1999;40(3):479–80.PubMedCrossRef

20.

Harrison PV, Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol. Clin Exp Dermatol. 1994;19(1):95.PubMedCrossRef

21.

Tchernev G, Chokoeva AA, Ivanova B, et al. Disseminated superficial actinic porokeratosis (DSAP): significant improvement after local administration of calcipotriol/betamethasone gel? Wien Med Wochenschr. 2016;. doi:10.1007/s10354-016-0484-8 (Epub ahead of print).

22.

Bakardzhiev I, Kavaklieva S, Pehlivanov G. Successful treatment of disseminated superficial actinic porokeratosis with calcipotriol. Int J Dermatol. 2012;51(9):1139–42. doi:10.1111/j.1365-4632.2010.04704.x.PubMedCrossRef

23.

Kohara Y, Takeo T, Oshima Y, et al. Linear porokeratosis with nail dystrophy. Eur J Dermatol. 2011;21(4):625–6. doi:10.1684/ejd.2011.1393.PubMed

24.

Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol. 1992;27(6 Pt 2):S8–14.PubMedCrossRef

25.

Garg T, Ramchander Varghese B, et al. Generalized linear porokeratosis: a rare entity with excellent response to acitretin. Dermatol Online J. 2011;17(5):3.PubMed

26.

Hong JB, Hsiao CH, Chu CY. Systematized linear porokeratosis: a rare variant of diffuse porokeratosis with good response to systemic acitretin. J Am Acad Dermatol. 2009;60(4):713–5. doi:10.1016/j.jaad.2008.10.011.PubMedCrossRef

27.

Dervis E, Demirkesen C. Generalized linear porokeratosis. Int J Dermatol. 2006;45(9):1077–9. doi:10.1111/j.1365-4632.2004.02490.x.PubMedCrossRef

28.

Grover C, Goel A, Nanda S, et al. A case of extensive linear porokeratosis with evaluation of topical tretinoin versus 5-flourouracil as treatment modalities. J Dermatol. 2005;32(12):1000–4.PubMedCrossRef

29.

Goldman GD, Milstone LM. Generalized linear porokeratosis treated with etretinate. Arch Dermatol. 1995;131(4):496–7.PubMedCrossRef

30.

Borroni RG, Poddighe D, Zecca M, Brazzelli V. Efficacy of acitretin for porokeratosis in a child with chronic cutaneous graft versus host disease. Pediatr Dermatol. 2013;30(1):148–50. doi:10.1111/j.1525-1470.2011.01610.x.PubMedCrossRef

31.

Uuskula A, Erm T. Disseminated giant hyperkeratotic porokeratosis and treatment with acitretin: a case report. Acta Derm Venereol. 2015;95(2):241–2. doi:10.2340/00015555-1908.PubMedCrossRef

32.

Hartman R, Mandal R, Sanchez M, Stein JA. Porokeratosis plantaris, palmaris, et disseminata. Dermatol Online J. 2010;16(11):22.PubMed

33.

Skroza N, Proietti I, Bernardini N, et al. Acitretin for treatment of familial porokeratosis palmaris et plantaris disseminate. Eur J Dermatol. 2012;22(5):699–700. doi:10.1684/ejd.2012.1826.PubMed

34.

Kumar SS, Lee S. Genitogluteal porokeratosis: an unusual clinical presentation. Aust J Dermatol. 2012;53(2):e36–9. doi:10.1111/j.1440-0960.2011.00784.x.CrossRef

35.

Tallon B, Blumental G, Bhawan J. Porokeratosis ptychotropica: a lesser-known variant. Clin Exp Dermatol. 2009;34(8):e895–7. doi:10.1111/j.1365-2230.2009.03664.x.PubMedCrossRef

36.

Uenishi T, Teramura K, Kitamura M, et al. Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits. J Dermatol. 2010;37(5):475–9. doi:10.1111/j.1346-8138.2010.00803.x.PubMedCrossRef

37.

Gotz A, Kopera D, Wach F, et al. Porokeratosis Mibelli gigantea: case report and literature review]. [Article in German. Hautarzt. 1999;50(6):435–8.PubMedCrossRef

38.

Agrawal SK, Gandhi V, Madan V, Bhattacharya SN. Topical tretinoin in Indian male with zosteriform porokeratosis. Int J Dermatol. 2003;42(11):919–20.PubMedCrossRef

39.

Gutierrez EL, Galarza C, Ramos W, et al. Facial porokeratosis: a series of six patients. Aust J Dermatol. 2010;51(3):191–4. doi:10.1111/j.1440-0960.2009.00616.x.CrossRef

40.

Suarez-Amor O, Pereiro-Ferreiros M, Ginarte M, et al. Coexistence of linear porokeratosis and disseminated superficial actinic porokeratosis: a type 2 segmental manifestation. Acta Derm Venereol. 2007;87(4):363–4. doi:10.2340/00015555-0215.PubMedCrossRef

41.

Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 Pt 2):S6–11.PubMedCrossRef

42.

Gajic B, Tang K, Whitfeld M. Porokeratosis of Mibelli: involution and resolution with 5% imiquimod cream. Aust J Dermatol. 2011;52(4):301–3. doi:10.1111/j.1440-0960.2010.00712.x.CrossRef

43.

Esser AC, Pittelkow MR, Randle HW. Human papillomavirus isolated from transplant-associated porokeratoses of mibelli responsive to topical 5% imiquimod cream. Dermatol Surg. 2006;32(6):858–61. doi:10.1111/j.1524-4725.2006.32176.x.PubMed

44.

Jain S. Successful treatment of porokeratosis of Mibelli with imiquimod 5% cream. Clin Exp Dermatol. 2006;31(2):302–3. doi:10.1111/j.1365-2230.2005.02044.x.PubMedCrossRef

45.

Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol. 2002;146(2):338–9.PubMedCrossRef

46.

Montes-De-Oca-Sanchez G, Tirado-Sanchez A, Garcia-Ramirez V. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. J Dermatol Treat. 2006;17(5):319–20. doi:10.1080/09546630600944116.CrossRef

47.

Gracia-Cazana T, Vera-Alvarez J, Garcia-Patos V, Gilaberte Y. Imiquimod and photodynamic therapy are useful in the treatment of porokeratosis in children with bone marrow transplantation. Pediatr Dermatol. 2015;32(6):e291–3. doi:10.1111/pde.12654.PubMedCrossRef

48.

Erbagci Z, Tuncel AA, Erbagci I. Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases. J Drugs Dermatol. 2006;5(7):668–71.PubMed

49.

Arun B, Pearson J, Chalmers R. Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. Clin Exp Dermatol. 2011;36(5):509–11. doi:10.1111/j.1365-2230.2011.04064.x.PubMedCrossRef

50.

Ahn SJ, Lee HJ, Chang SE, et al. Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol. 2007;34(2):146–7. doi:10.1111/j.1346-8138.2006.00236.x.PubMedCrossRef

51.

Kindem S, Serra-Guillen C, Sorni G, et al. Treatment of porokeratosis of Mibelli with ingenol mebutate: a possible new therapeutic option. JAMA Dermatol. 2015;151(1):85–6. doi:10.1001/jamadermatol.2014.2697.PubMedCrossRef

52.

Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatol Treat. 2009;20(6):328–35. doi:10.3109/09546630902789326.CrossRef

53.

Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream. Aust J Dermatol. 2003;44(4):281–3.CrossRef

54.

Chowdhury MM, Inaloz HS, Holt PJ. A scaly macule on the bridge of the nose of a 15-year-old boy. Pediatr Dermatol. 2000;17(2):149–50.PubMedCrossRef

55.

Danby W. Treatment of porokeratosis with fluorouracil and salicylic acid under occlusion. Dermatol Online J. 2003;9(5):33.PubMed

56.

Venkatarajan S, LeLeux TM, Yang D, et al. Porokeratosis of Mibelli: successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil. Dermatol Online J. 2010;16(12):10.PubMed

57.

Teixeira SP, de Nascimento MM, Bagatin E, et al. The use of fluor-hydroxy pulse peel in actinic porokeratosis. Dermatol Surg. 2005;31(9 Pt 1):1145–8.PubMedCrossRef

58.

Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. Am J Clin Derm. 2007;8(4):195–200.CrossRef

59.

Marks S, Varma R, Cantrell W, et al. Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol. 2009;23(1):42–5. doi:10.1111/j.1468-3083.2008.02943.x.PubMedCrossRef

60.

Kluger N, Dereure O, Guilhou JJ, Guillot B. Genital porokeratosis: treatment with diclofenac topical gel. J Dermatol Treat. 2007;18(3):188–90. doi:10.1080/09546630701258101.CrossRef

61.

Vlachou C, Kanelleas AI, Martin-Clavijo A, Berth-Jones J. Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series. J Eur Acad Dermatol Venereol. 2008;22(11):1343–5. doi:10.1111/j.1468-3083.2008.02842.x.PubMedCrossRef

62.

Tee SI, Chong WS. Eruptive pruritic papular porokeratosis. Indian J Dermatol Venereol Leprol. 2012;78(6):758–60. doi:10.4103/0378-6323.102384.PubMedCrossRef

63.

Verma KK, Singh OP. Dexamethasone pulse treatment in disseminated porokeratosis of Mibelli. J Dermatol Sci. 1994;7(1):71–2.PubMedCrossRef

64.

Klein N, Enk A, Hartschuh W. Inflammatory stage of disseminated superficial porokeratosis in a 71-year old patient]. [Article in German. Hautarzt. 2009;60(5):420–3. doi:10.1007/s00105-008-1639-3.PubMedCrossRef

65.

Chen TJ, Chou YC, Chen CH, et al. Genital porokeratosis: a series of 10 patients and review of the literature. Br J Dermatol. 2006;155(2):325–9. doi:10.1111/j.1365-2133.2006.07295.x.PubMedCrossRef

66.

Kim DS, Roh MR, Lee JH, Lee KH. Pterygium unguis formation in porokeratosis of Mibelli. Br J Dermatol. 2007;156(6):1384–5. doi:10.1111/j.1365-2133.2007.07887.x.PubMedCrossRef

67.

Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs. 2005;65(6):827–58.PubMedCrossRef

68.

Parks AC, Conner KJ, Armstrong CA. Long-term clearance of linear porokeratosis with tacrolimus, 01%, ointment. JAMA Dermatol. 2014;150(2):194–6. doi:10.1001/jamadermatol.2013.8526.PubMedCrossRef

69.

Rabbin PE, Baldwin HE. Treatment of porokeratosis of Mibelli with CO₂ laser vaporization versus surgical excision with split-thickness skin graft: a comparison. J Dermatol Surg Oncol. 1993;19(3):199–202.PubMedCrossRef

70.

Merkle T, Hohenleutner U, Braun-Falco O, Landthaler M. Reticulate porokeratosis: successful treatment with CO₂-laser vaporization. Clin Exp Dermatol. 1992;17(3):178–81.PubMedCrossRef

71.

Hernandez-Bel P, Sanmartin-Jimenez O, Sorni-Broker G, Guillen-Barona C. Labial porokeratosis. Am J Dermatopathol. 2010;32(6):638. doi:10.1097/DAD.0b013e3181caac93.PubMedCrossRef

72.

Kim HS, Baek JH, Park YM, et al. Photodynamic therapy combined with CO(2) laser vaporization on disseminated superficial actinic porokeratosis: a report of 2 cases on the face. Ann Dermatol. 2011;23(Suppl. 2):S211–3. doi:10.5021/ad.2011.23.S2.S211.PubMedPubMedCentralCrossRef

73.

McCullough TL, Lesher JL Jr. Porokeratosis of Mibelli: rapid recurrence of a large lesion after carbon dioxide laser treatment. Pediatr Dermatol. 1994;11(3):267–70.PubMedCrossRef

74.

Itoh M, Nakagawa H. Successful treatment of disseminated superficial actinic porokeratosis with Q-switched ruby laser. J Dermatol. 2007;34(12):816–20. doi:10.1111/j.1346-8138.2007.00392.x.PubMedCrossRef

75.

Lee DK, Oh SH, Chang SE, et al. A rare variant of porokeratosis: porokeratosis ptychotropica. J Am Acad Dermatol. 2006;55(5 Suppl.):S120–2. doi:10.1016/j.jaad.2005.12.009.PubMedCrossRef

76.

Liu Y, Wang Y, Nie X, et al. Treatment of classic porokeratosis of Mibelli with Q-switched ruby laser. Eur J Dermatol. 2012;22(1):125–6. doi:10.1684/ejd.2011.1552.PubMed

77.

Lolis MS, Marmur ES. Treatment of disseminated superficial actinic porokeratosis (DSAP) with the Q-switched ruby laser. J Cosmet Laser Ther. 2008;10(2):124–7. doi:10.1080/14764170802068971.PubMedCrossRef

78.

Rosenblum J, Roenigk HH Jr. Erbium laser for the treatment of disseminated superficial actinic porokeratosis: a case report. Dermatol Surg. 2013;39(10):1543–5. doi:10.1111/dsu.12261.PubMed

79.

Liu HT. Treatment of lichen amyloidosis (LA) and disseminated superficial porokeratosis (DSP) with frequency-doubled Q-switched Nd:YAG laser. Dermatol Surg. 2000;26(10):958–62.PubMedCrossRef

80.

Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch Dermatol. 2007;143(11):1450–2. doi:10.1001/archderm.143.11.1450.PubMedCrossRef

81.

Alster TS, Nanni CA. Successful treatment of porokeratosis with 585 nm pulsed dye laser irradiation. Cutis. 1999;63(5):265–6.PubMed

82.

Ricci C, Rosset A, Panizzon RG. Bullous and pruritic variant of disseminated superficial actinic porokeratosis: successful treatment with grenz rays. Dermatology. 1999;199(4):328–31. doi:10.1159/000018284.PubMedCrossRef

83.

Wolf P. Photodynamic therapy in dermatology: state of the art. J Eur Acad Dermatol Venereol. 2001;15(6):508–9.PubMedCrossRef

84.

Fernandez-Guarino M, Harto A, Perez-Garcia B, et al. Photodynamic therapy in disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol. 2009;23(2):176–7. doi:10.1111/j.1468-3083.2008.02753.x.PubMedCrossRef

85.

Cavicchini S, Tourlaki A. Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy. J Dermatol Treat. 2006;17(3):190–1. doi:10.1080/09546630600788869.CrossRef

86.

Calzavara-Pinton PG, Rossi MT, Italian Group For Photodynamic T, et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications. Photochem Photobiol Sci. 2013;12(1):148–57. doi:10.1039/c2pp25124h.PubMedCrossRef

87.

Gutierrez Paredes E, Bella Navarro R, Montesinos Villaescusa E, Jorda Cuevas E. Porokeratosis of Mibelli: a new indication for photodynamic therapy? Actas Dermosifiliogr. 2013;104(3):259–61. doi:10.1016/j.ad.2012.04.016.PubMedCrossRef

88.

Giuliodori K, Campanati A, Ganzetti G, et al. The successful off-label use of photodynamic therapy for classic porokeratosis of Mibelli: case report. Dermatol Ther. 2011;24(5):501–4. doi:10.1111/j.1529-8019.2012.01473.x.PubMedCrossRef

89.

Curkova AK, Hegyi J, Kozub P, et al. A case of linear porokeratosis treated with photodynamic therapy with confocal microscopy surveillance. Dermatol Ther. 2014;27(3):144–7. doi:10.1111/dth.12097.PubMedCrossRef

90.

Garcia-Navarro X, Garces JR, Baselga E, Alomar A. Linear porokeratosis: excellent response to photodynamic therapy. Arch Dermatol. 2009;145(5):526–7. doi:10.1001/archdermatol.2009.45.PubMedCrossRef

91.

Boiy A, de Witte PA, Roelandts R. Topical treatment of disseminated superficial actinic porokeratosis with hypericin-photodynamic therapy: a case report. Photodiagnosis Photodyn Ther. 2010;7(2):123–5. doi:10.1016/j.pdpdt.2010.02.003.PubMedCrossRef

92.

Garrido-Colmenero C, Ruiz-Villaverde R, Martinez-Garcia E, et al. Photoletter to the editor: response of linear porokeratosis to photodynamic therapy in an 11-year-old girl. J Dermatol Case Rep. 2015;9(4):118–9. doi:10.3315/jdcr.2015.1220.PubMedPubMedCentralCrossRef

93.

Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol. 2002;27(8):703–6.PubMedCrossRef

94.

Levitt J, Emer JJ, Emanuel PO. Treatment of porokeratosis of mibelli with combined use of photodynamic therapy and fluorouracil cream. Arch Dermatol. 2010;146(4):371–3. doi:10.1001/archdermatol.2010.28.PubMedCrossRef

95.

Salas T, Hernandez-Gil J, Lopez A, et al. Two cases of disseminated superficial actinic porokeratosis treated with daylight-mediated photodynamic therapy. Dermatol Ther. 2016;29(6):484–5. doi:10.1111/dth.12389.PubMedCrossRef

96.

Piccolo D, Di Marcantonio D, Crisman G, et al. Unconventional use of intense pulsed light. BioMed Res Int. 2014;2014:618206. doi:10.1155/2014/618206.PubMedPubMedCentralCrossRef

97.

Spencer JM, Katz BE. Successful treatment of porokeratosis of Mibelli with diamond fraise dermabrasion. Arch Dermatol. 1992;128(9):1187–8.PubMedCrossRef

98.

Cohen PR, Held JL, Katz BE. Linear porokeratosis: successful treatment with diamond fraise dermabrasion. J Am Acad Dermatol. 1990;23(5 Pt 2):975–7.PubMedCrossRef

99.

Alexis AF, Busam K, Myskowski PL. Porokeratosis of Mibelli following bone marrow transplantation. Int J Dermatol. 2006;45(4):361–5. doi:10.1111/j.1365-4632.2006.02509.x.PubMedCrossRef

100.

Otani Y, Katagiri K, Takeuchi Y, et al. A case of giant porokeratosis with vestiges of a cornoid lamella. J Dermatol. 2005;32(11):894–8.PubMedCrossRef

101.

Scheiba N, Enk A, Proske S, Hartschuh W. Porokeratosis ptychotropica: successful treatment with the dermatome. Dermatol Surg. 2010;36(2):257–60. doi:10.1111/j.1524-4725.2009.01402.x.PubMedCrossRef

102.

Robinson JB, Im DD, Jockle G, Rosenshein NB. Vulvar porokeratosis: case report and review of the literature. Int J Gynecol Pathol. 1999;18(2):169–73.PubMedCrossRef

103.

Yazkan F, Turk BG, Dereli T, Kazandi AC. Porokeratosis of Mibelli induced by topical corticosteroid. J Cutan Pathol. 2006;33(7):516–8. doi:10.1111/j.1600-0560.2006.00464.x.PubMedCrossRef

104.

Levell NJ, Bewley AP, Levene GM. Porokeratosis of Mibelli on the penis, scrotum and natal cleft. Clin Exp Dermatol. 1994;19(1):77–8.PubMedCrossRef

105.

Bhushan M, Craven NM, Beck MH, Chalmers RJ. Linear porokeratosis of Mibelli: successful treatment with cryotherapy. Br J Dermatol. 1999;141(2):389.PubMedCrossRef

106.

Vergara G, Banuls J, Botella R, et al. Porokeratosis of the lower lip. Eur J Dermatol. 2002;12(5):500–2.PubMed

107.

Goncalves SV, Valente NY, Oliveira Jrunior JV, Paiva DL. Case for diagnosis. An Braz Dermatol. 2012;87(3):489–90.CrossRef

108.

Dereli T, Ozyurt S, Ozturk G. Porokeratosis of Mibelli: successful treatment with cryosurgery. J Dermatol. 2004;31(3):223–7.PubMedCrossRef

Titel: Treatment of Porokeratosis: A Systematic Review
verfasst von: Till Weidner
Tanja Illing
Diana Miguel
Peter Elsner
Publikationsdatum: 01.08.2017
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 4/2017
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-017-0271-3

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP)

Cutaneous Manifestations of Diabetes Mellitus: A Review

Black Hairy Tongue: Predisposing Factors, Diagnosis, and Treatment

Morphea and Eosinophilic Fasciitis: An Update

Topical Botanical Agents for the Treatment of Psoriasis: A Systematic Review